Johnson & Johnson vs. Moleculin Biotech, Inc.
Johnson & Johnson (JNJ) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| JNJ | MBRX | |
|---|---|---|
| Market Cap | $655.37 billion | $15.06 million |
| Revenue (TTM) | $97.93 billion | — |
| Net Income (TTM) | $21.04 billion | — |
JNJ leads on 1 of 1 size & scale factors.
Valuation
| JNJ | MBRX | |
|---|---|---|
| P/E Ratio | 31.55 | — |
| Price / Book | 7.71 | — |
| Price / Sales | 6.69 | — |
JNJ and MBRX split the valuation factors evenly.
Profitability
| JNJ | MBRX | |
|---|---|---|
| Net Margin | 21.48% | — |
| Return on Equity | 24.76% | — |
JNJ and MBRX split the profitability factors evenly.
Dividend
| JNJ | MBRX | |
|---|---|---|
| Dividend Yield | 1.97% | — |
| Payout Ratio | 62.18 | — |
JNJ and MBRX split the dividend factors evenly.
Risk & Sentiment
| JNJ | MBRX | |
|---|---|---|
| Short Interest | 0.67% | 7.72% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, MBRX overview, MBRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.